Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP17A1 | P05093 | 2/20 | 0.47 |
| ▸ | KCNQ4 | P56696 | 4/20 | 0.46 |
| ▸ | KCNQ5 | Q9NR82 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.37 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.37 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | AKT1 | P31749 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16245955 | 0.88 | CYP17A1 (0.48) | CYP17A1KCNQ4KCNQ5MEN1KMT2A | |
| SCHEMBL28207323 | 0.85 | CYP17A1 (0.50) | CYP17A1KCNQ4KCNQ5POLBMAPK14 | |
| SCHEMBL3832059 | 0.84 | KCNQ4 (0.50) | CYP17A1KCNQ4KCNQ5POLBRXFP1 | |
| SCHEMBL29468015 | 0.84 | CYP17A1 (0.49) | CYP17A1KCNQ4KCNQ5POLBRXFP1 | |
| SCHEMBL27772977 | 0.82 | CYP17A1 (0.47) | CYP17A1KCNQ4KCNQ5POLBMAPK14 | |
| SCHEMBL23637704 | 0.80 | CYP17A1 (0.47) | CYP17A1KCNQ4KCNQ5MAPK14 | |
| SCHEMBL478362 | 0.79 | CYP17A1 (0.52) | CYP17A1KCNQ4KCNQ5RAB9ARXFP1 | |
| SCHEMBL29659087 | 0.79 | CYP17A1 (0.52) | CYP17A1KCNQ4KCNQ5RAB9ARXFP1 | |
| SCHEMBL31347221 | 0.79 | CYP17A1 (0.52) | CYP17A1KCNQ4KCNQ5POLBRAB9A | |
| SCHEMBL857284 | 0.79 | HTT (0.55) | CYP17A1KCNQ4KCNQ5POLBRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2994470-B1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9630963-B2 | Quinolone derivatives as fibroblast growth factor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160130268-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. | 2016-05-12 | — | — | US | disclosed |
| EP-2994470-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | Principia Biopharma Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| WO-2014182829-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-11-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160130268-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | FGFR1, FGFR3, FGFR2 | CYP17A1 1380/4885KCNQ4 2655/4885KCNQ5 2245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.